# CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2015

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2015-08-04
- Accepted by EDGAR: Aug 4, 2015, 16:54 ET
- Period: 2015-06-30
- Accession: 0000064803-15-000054
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000006480315000054/cvs20150630-10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000006480315000054/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-04-01 to 2015-06-30 | $37.17bn | us-gaap:Revenues |
| Revenue | 6 months, 2015-01-01 to 2015-06-30 | $73.50bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-04-01 to 2015-06-30 | $30.77bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2015-01-01 to 2015-06-30 | $60.94bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-04-01 to 2015-06-30 | $6.40bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2015-01-01 to 2015-06-30 | $12.57bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | $2.26bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-01-01 to 2015-06-30 | $4.39bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-04-01 to 2015-06-30 | $171.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2015-01-01 to 2015-06-30 | $309.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-04-01 to 2015-06-30 | $824.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2015-01-01 to 2015-06-30 | $1.60bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 6 months, 2015-01-01 to 2015-06-30 | $2.49bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | $1.12 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2015-01-01 to 2015-06-30 | $2.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-04-01 to 2015-06-30 | $1.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2015-01-01 to 2015-06-30 | $2.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-04-01 to 2015-06-30 | 1,132,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2015-01-01 to 2015-06-30 | 1,134,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2015-01-01 to 2015-06-30 | $3.02bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2015-01-01 to 2015-06-30 | $942.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2015-01-01 to 2015-06-30 | $794.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2015-01-01 to 2015-06-30 | $2.93bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2015-06-30 | $1.24bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-06-30 | $26.40bn | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $74.67bn | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $20.39bn | us-gaap:LiabilitiesCurrent |
| Short-term borrowings | at 2015-06-30 | $1.49bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2015-06-30 | $37.13bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 993 characters.

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended June 30, 2015, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2014 and 2013 Repurchase Programs. See Note 6 to the condensed consolidated financial statements.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| April 1, 2015 through April 30, 2015 | — | $— | — | $10,684,839,660 |
| May 1, 2015 through May 31, 2015 | 6,627,747 | $101.01 | 6,627,747 | $10,325,000,777 |
| June 1, 2015 through June 30, 2015 | 5,502,915 | $103.01 | 5,502,915 | $9,758,158,370 |
| Totals | 12,130,662 |  | 12,130,662 |  |

38

## Market risk

As filed, 335 characters.

As of June 30, 2015, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of June 30, 2015 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

## Controls and procedures

As filed, 1,052 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of June 30, 2015, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,778 characters.

In the three months ended June 30, 2015, the Company has entered into acquisition agreements under which it proposes to acquire Omnicare, Inc., (“Omnicare”) and the pharmacy and clinic assets of Target Corporation (“Target”). Both proposed acquisitions resulted in a change in the factors set forth under “Cautionary Statement Concerning Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The following risk factors have been identified by the Company in the three months ended June 30, 2015, as a result of the proposed acquisition agreements.

### Risks relating to pending acquisitions.

The acquisition agreements we enter into typically contain closing conditions, including those related to our proposed acquisitions of Omnicare and the pharmacy and clinic assets of Target. Our ability to consummate pending acquisitions is subject to the satisfaction of these conditions. For example, our contemplated acquisition of Omnicare is subject to the satisfaction of closing conditions, including (i) approval by the stockholders of Omnicare, (ii) the receipt of regulatory approvals, and (iii) certain other customary closing conditions. Even if all of the closing conditions for a particular acquisition are satisfied, we cannot assure you that the acquisition will close on our expected timeframe or at all. Certain acquisition agreements we enter into obligate us to pay, under certain circumstances, termination fees in the event that an acquisition is not consummated. Failure to complete a particular acquisition or any delays in completing the acquisition could prevent us from realizing the benefits of the acquisition and could have an adverse impact on our business.

### We may be unable to successfully integrate companies acquired by us.

Upon the closing of any acquisition we complete, we will need to successfully integrate the products, services and related assets into our business operations. If an acquisition is consummated, the integration of the acquired business, its products, services and related assets into our company may also be complex and time-consuming and, if the integration is not fully successful, we may not achieve the anticipated benefits, operating and cost synergies or growth opportunities of an acquisition. Potential difficulties that may be encountered in the integration process include the following:

- Integrating personnel, operations and systems, while maintaining focus on producing and delivering consistent, high quality products and services;
- Coordinating geographically dispersed organizations;
- Disruption of management’s attention from our ongoing business operations;
- Retaining existing customers and attracting new customers; and
- Managing inefficiencies associated with integrating our operations.

An inability to realize the full extent of the anticipated benefits, operating and cost synergies or growth opportunities of an acquisition, as well as any delays encountered in the integration process, could have a material adverse effect on our business and results of operation, which may affect the value of the shares of our common stock after the completion of an acquisition. Furthermore, these acquisitions, even if successfully integrated, may fail to further our business strategy as anticipated, expose us to increased competition or challenges with respect to our products, services or geographic markets, and expose us to additional liabilities associated with an acquired business including risks and liabilities associated with litigation involving the acquired business. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisitions after we have expended resources on them.

Filed Aug 4, 2015.
Source: SEC EDGAR, the filing index for accession 0000064803-15-000054. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
